
A New Era of Cancer Reassessment in Hong Kong: The Potential of RGCC Oncotrace Testing
With advancements in cancer care, patient survival rates have improved significantly. However, recurrence and metastasis remain major challenges in cancer management. In Hong Kong, the accuracy and timeliness of cancer reassessment are crucial in improving patient outcomes. Traditional imaging techniques and blood tumor markers provide valuable information but often fail to detect early signs of recurrence. The RGCC Oncotrace test, utilizing liquid biopsy technology, integrates circulating tumor cell (CTC) detection, gene expression analysis, and drug sensitivity testing. This breakthrough enables early recurrence detection and personalized reassessment strategies, marking a new era in cancer surveillance.








